S-8 1 olma-20260316.htm S-8 S-8

As filed with the Securities and Exchange Commission on March 16, 2026

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form S‑8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

Olema Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)



Delaware		30‑0409740
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

780 Brannan Street San Francisco, California (Address of Principal Executive Offices)		94103 (Zip Code)

2020 Equity Incentive Plan

2020 Employee Stock Purchase Plan

(Full titles of the plans)

Sean Bohen, M.D., Ph.D.

Chief Executive Officer and President

780 Brannan Street

San Francisco, California 94103

(415) 651‑3316

(Name, address and telephone number, including area code, of agent for service)

Copies to:

Yvan-Claude Pierre

Julia R. Boesch

Cooley LLP

55 Hudson Yards

New York, New York 10001

(212) 479‑6000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.



Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

EXPLANATORY NOTE

Olema Pharmaceuticals, Inc. (the “Registrant”) is filing this Registration Statement on Form S‑8 (this “Registration Statement”) to register 2,906,100 shares of common stock, par value $0.0001 per share (“Common Stock”), of the Registrant reserved for issuance under the Olema Pharmaceuticals, Inc. 2020 Equity Incentive Plan (the “Plan”); 1,162,722 shares of Common Stock that may be issued upon the exercise of outstanding options granted under the Plan; and 813,764 shares of Common Stock reserved for issuance under the Olema Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan (the “ESPP”).

These additional shares of Common Stock are securities of the same class as other securities previously registered for issuance under the Plan and the ESPP pursuant to (i) a Registration Statement on Form S‑8 (File No. 333‑250209) filed with the Securities and Exchange Commission (the “Commission”) on November 19, 2020, (ii) a Registration Statement on Form S‑8 (File No. 333‑254403) filed with the Commission on March 17, 2021, (iii) a Registration Statement on Form S‑8 (File No. 333‑263114) filed with the Commission on March 1, 2022, (iv) a Registration Statement on Form S-8 (File No. 333-270413) filed with the Commission on March 9, 2023, (v) a Registration Statement on Form S-8 (File No. 333-277820) filed with the Commission on March 11, 2024, and (vi) a Registration Statement on Form S-8 (File No. 333-285882) filed with the Commission on March 18, 2025 (collectively, the “Prior Registration Statements”). Accordingly, the contents of the Prior Registration Statements are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S‑8. The additional shares of Common Stock reserved for issuance under the Plan and the ESPP have become reserved for issuance thereunder pursuant to the provisions of the Plan and the ESPP providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance thereunder on January 1, 2026.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

(a)

The Registrant’s Annual Report on Form 10‑K for the fiscal year ended December 31, 2025 (the “Annual Report”), filed with the Commission on March 16, 2026.

(b)

The Registrant’s Current Report on Form 8-K filed with the Commission on January 30, 2026.

(c)

The description of the Registrant’s Common Stock that is contained in a registration statement on Form 8‑A filed on November 17, 2020 (File No. 001‑39712) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Commission on March 17, 2021.

(d)

All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8‑K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Item 8. Exhibits.



Exhibit Number		Exhibit Description
4.1		Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Form 8‑K (File No. 001‑39712), filed with the Commission on November 23, 2020).
4.2		Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Form 8‑K (File No. 001‑39712), filed with the Commission on December 16, 2022).
4.3		Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S‑1 (File No. 333‑249748), filed with the Commission on November 16, 2020).
4.4		Description of Capital Stock (incorporated herein by reference to Exhibit 4.3 to the Registrant’s Form 10-K (File No. 001-39712), filed with the Commission on March 17, 2021).
5.1*		Opinion of Cooley LLP.
23.1*		Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.
23.2*		Consent of Cooley LLP (included in Exhibit 5.1).
24.1*		Power of Attorney (reference is made to the signature page hereto).
99.1		Olema Pharmaceuticals, Inc. 2020 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S‑1/A (File No. 333‑249748), filed with the Commission on November 16, 2020).
99.2		Olema Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-249748), filed with the Commission on November 16, 2020).
107*		Filing Fee Table.

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California on March 16, 2026.



	Olema Pharmaceuticals, Inc.

	By:	/s/ Sean Bohen
		Sean Bohen, M.D., Ph.D.
		President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sean Bohen, M.D., Ph.D. and Shawnte Mitchell, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S‑8 has been signed by the following persons in the capacities and on the dates indicated.


Signature	Title	Date
/s/ Sean Bohen	President, Chief Executive Officer and Director	March 16, 2026
Sean Bohen, M.D., Ph.D.	(Principal Executive Officer and Principal Financial Officer)

/s/ Sasha Austin	Vice President, Finance and Controller	March 16, 2026
Sasha Austin

/s/ Ian Clark	Chairperson of the Board	March 16, 2026
Ian Clark

/s/ Cynthia Butitta	Director	March 16, 2026
Cynthia Butitta

/s/ Scott Garland	Director	March 16, 2026
Scott Garland

/s/ Cyrus L. Harmon	Director	March 16, 2026
Cyrus L. Harmon, Ph.D.

/s/ Sandra Horning, M.D.	Director	March 16, 2026
Sandra Horning, M.D.

/s/ Gorjan Hrustanovic	Director	March 16, 2026
Gorjan Hrustanovic, Ph.D.

/s/ Yi Larson	Director	March 16, 2026
Yi Larson

/s/ Andrew Rappaport	Director	March 16, 2026
Andrew Rappaport

/s/ Graham Walmsley	Director	March 16, 2026
Graham Walmsley, M.D., Ph.D.

SEC Form S-8 filed by Olema Pharmaceuticals Inc.